HIV type 1 (HIV-1) is the causative agent of AIDS. Since the start of the epidemic, HIV/AIDS
has been responsible for≈ 40 million deaths. Additionally, an estimated 39 million people …

In people living with HIV (PLWH) on antiretroviral therapy (ART), virus persists in a latent
form where there is minimal transcription or protein expression. Latently infected cells are a …

Importance Therapies targeting the programmed cell death 1 (PD-1) receptor or its ligand
(PD-L1), such as the humanized monoclonal antibody durvalumab, have shown durable …

Immunodeficiency, whether acquired in the case of human immunodeficiency virus (HIV)
infection or congenital due to inborn errors of immunity (IEIs), presents clinically with not only …

Cancer is the second leading cause of death in the worldwide. With the growing burden of
cancer, the studies on early diagnosis, treatment and prevention of cancer are rapidly …

Importance Anti–programmed death 1 and anti–programmed death ligand 1 (anti–
PD1/PDL1) immune checkpoint blockade (ICB) constitutes the therapeutic backbone for …

Blockade of the co-inhibitory receptor PD-1 enhances antitumor responses by boosting the
function of antigen-specific T cells. Although rare, PD-1 blockade in patients with cancer can …

Introduction This study aimed to compare demographics, disease characteristics, and
outcomes of patients with HIV-infection with non–small-cell lung cancer (NSCLC) with the …

Since antiretroviral therapy became widely available in the late 1990s, there has been a
dramatic reduction in AIDS-related deaths due to opportunistic infections. 1 The life …

Цель исследования-представить имеющиеся данные о переносимости ингибиторов
контрольных точек (ИКТ) у онкологических пациентов, отягощенных ВИЧ-инфекцией …